Current Cancer Drug Targets
Title:Meet Our Editorial Board Member
Volume: 17 Issue: 4
Author(s): Thomas W. Grunt*
Affiliation:
- Signaling Networks Program, Comprehensive Cancer Center, Ludwig Boltzmann Cluster Oncology, Medical University Vienna,Austria
Export Options
About this article
Cite this article as:
Grunt W. Thomas*, Meet Our Editorial Board Member, Current Cancer Drug Targets 2017; 17 (4) . https://dx.doi.org/10.2174/156800961704170419204900
DOI https://dx.doi.org/10.2174/156800961704170419204900 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
28
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Curcumin Targets in Inflammation and Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Regulation of Autophagy in Oxygen-Dependent Cellular Stress
Current Pharmaceutical Design Glycosphingolipid Structure and Function in Membranes
Current Organic Chemistry Part II: Targeted Particles for Imaging of Anticancer Immune Responses
Current Drug Delivery Applications of FDG-PET/CT in Assessment of Vascular Infection and Inflammation
Current Molecular Imaging (Discontinued) Interaction of Endocannabinoid Receptors with Biological Membranes
Current Medicinal Chemistry A Carboxylesterase 2 Gene Polymorphism as Predictor of Capecitabine on Response and Time to Progression
Current Drug Metabolism Preface
Current Pharmaceutical Design Preclinical Evaluation of New Anthracyclines
Current Medicinal Chemistry The Role of Apoptotic Dysfunction in the Pathogenesis of Endometriosis
Current Women`s Health Reviews Lactose and Casein Cause Changes on Biomarkers of Oxidative Damage and Dysbiosis in an Experimental Model of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets NUPR1 Interacts with p53, Transcriptionally Regulates p21 and Rescues Breast Epithelial Cells from Doxorubicin-Induced Genotoxic Stress
Current Cancer Drug Targets Screening of SLE-susceptible SNPs in One Chinese Family with Systemic Lupus Erythematosus
Current Bioinformatics Pharmacological Drug Delivery Strategies for Improved Therapeutic Effects: Recent Advances
Current Pharmaceutical Design Structure, DNA Binding and Cytotoxicity Studies of [Cu(D-glu)(phen)(H2O)]•NO3•2H2O
Letters in Drug Design & Discovery Nongenomic Actions of Retinoids: Role of Nur77 and RXR in the Regulation of Apoptosis and Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry CD26: A Multi-Purpose Pharmacological Target
Current Clinical Pharmacology PIM1 Kinase as a Target in Prostate Cancer: Roles in Tumorigenesis, Castration Resistance, and Docetaxel Resistance
Current Cancer Drug Targets Peptide Therapeutics and the Pharmaceutical Industry: Barriers Encountered Translating from the Laboratory to Patients
Current Medicinal Chemistry Anticancer Drug Design Using Scaffolds of β-Lactams, Sulfonamides, Quinoline, Quinoxaline and Natural Products. Drugs Advances in Clinical Trials
Current Medicinal Chemistry